Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program

Min H. Kang, C. Patrick Reynolds, John M. Maris, Richard Gorlick, E. Anders Kolb, Richard Lock, Hernan Carol, Stephen T. Keir, Jianrong Wu, Dmitry Lyalin, Raushan T. Kurmasheva, Peter J. Houghton, Malcolm A. Smith

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

MLN0128 is an investigational small molecule ATP-competitive inhibitor of the serine/threonine kinase mTOR. MLN0128 was tested against the in vitro panel at concentrations ranging from 0.1nM to 1μM and against the PPTP in vivo panels at a dose of 1mg/kg administered orally daily×28. In vitro the median relative IC50 concentration was 19nM. In vivo MLN0128 induced significant differences in EFS in 24/31 (77%) solid tumor models, but 0/7 ALL xenografts. The modest activity observed for MLN0128 against the PPTP preclinical models is similar to that previously reported for another TOR kinase inhibitor.

Original languageEnglish (US)
Pages (from-to)1486-1489
Number of pages4
JournalPediatric Blood and Cancer
Volume61
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Phosphotransferases
TOR Serine-Threonine Kinases
Pediatrics
Heterografts
Inhibitory Concentration 50
Adenosine Triphosphate
INK128
Neoplasms
N-propyl-4-phenyl-1,2,3,6-tetrahydropyridine
In Vitro Techniques

Keywords

  • Developmental therapeutics
  • MTOR inhibitor
  • Preclinical testing

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Kang, M. H., Reynolds, C. P., Maris, J. M., Gorlick, R., Kolb, E. A., Lock, R., ... Smith, M. A. (2014). Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 61(8), 1486-1489. https://doi.org/10.1002/pbc.24989

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. / Kang, Min H.; Reynolds, C. Patrick; Maris, John M.; Gorlick, Richard; Kolb, E. Anders; Lock, Richard; Carol, Hernan; Keir, Stephen T.; Wu, Jianrong; Lyalin, Dmitry; Kurmasheva, Raushan T.; Houghton, Peter J.; Smith, Malcolm A.

In: Pediatric Blood and Cancer, Vol. 61, No. 8, 2014, p. 1486-1489.

Research output: Contribution to journalArticle

Kang, MH, Reynolds, CP, Maris, JM, Gorlick, R, Kolb, EA, Lock, R, Carol, H, Keir, ST, Wu, J, Lyalin, D, Kurmasheva, RT, Houghton, PJ & Smith, MA 2014, 'Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 61, no. 8, pp. 1486-1489. https://doi.org/10.1002/pbc.24989
Kang, Min H. ; Reynolds, C. Patrick ; Maris, John M. ; Gorlick, Richard ; Kolb, E. Anders ; Lock, Richard ; Carol, Hernan ; Keir, Stephen T. ; Wu, Jianrong ; Lyalin, Dmitry ; Kurmasheva, Raushan T. ; Houghton, Peter J. ; Smith, Malcolm A. / Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. In: Pediatric Blood and Cancer. 2014 ; Vol. 61, No. 8. pp. 1486-1489.
@article{8d81ff59919443ea8ec87bc72c9c02c6,
title = "Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program",
abstract = "MLN0128 is an investigational small molecule ATP-competitive inhibitor of the serine/threonine kinase mTOR. MLN0128 was tested against the in vitro panel at concentrations ranging from 0.1nM to 1μM and against the PPTP in vivo panels at a dose of 1mg/kg administered orally daily×28. In vitro the median relative IC50 concentration was 19nM. In vivo MLN0128 induced significant differences in EFS in 24/31 (77{\%}) solid tumor models, but 0/7 ALL xenografts. The modest activity observed for MLN0128 against the PPTP preclinical models is similar to that previously reported for another TOR kinase inhibitor.",
keywords = "Developmental therapeutics, MTOR inhibitor, Preclinical testing",
author = "Kang, {Min H.} and Reynolds, {C. Patrick} and Maris, {John M.} and Richard Gorlick and Kolb, {E. Anders} and Richard Lock and Hernan Carol and Keir, {Stephen T.} and Jianrong Wu and Dmitry Lyalin and Kurmasheva, {Raushan T.} and Houghton, {Peter J.} and Smith, {Malcolm A.}",
year = "2014",
doi = "10.1002/pbc.24989",
language = "English (US)",
volume = "61",
pages = "1486--1489",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program

AU - Kang, Min H.

AU - Reynolds, C. Patrick

AU - Maris, John M.

AU - Gorlick, Richard

AU - Kolb, E. Anders

AU - Lock, Richard

AU - Carol, Hernan

AU - Keir, Stephen T.

AU - Wu, Jianrong

AU - Lyalin, Dmitry

AU - Kurmasheva, Raushan T.

AU - Houghton, Peter J.

AU - Smith, Malcolm A.

PY - 2014

Y1 - 2014

N2 - MLN0128 is an investigational small molecule ATP-competitive inhibitor of the serine/threonine kinase mTOR. MLN0128 was tested against the in vitro panel at concentrations ranging from 0.1nM to 1μM and against the PPTP in vivo panels at a dose of 1mg/kg administered orally daily×28. In vitro the median relative IC50 concentration was 19nM. In vivo MLN0128 induced significant differences in EFS in 24/31 (77%) solid tumor models, but 0/7 ALL xenografts. The modest activity observed for MLN0128 against the PPTP preclinical models is similar to that previously reported for another TOR kinase inhibitor.

AB - MLN0128 is an investigational small molecule ATP-competitive inhibitor of the serine/threonine kinase mTOR. MLN0128 was tested against the in vitro panel at concentrations ranging from 0.1nM to 1μM and against the PPTP in vivo panels at a dose of 1mg/kg administered orally daily×28. In vitro the median relative IC50 concentration was 19nM. In vivo MLN0128 induced significant differences in EFS in 24/31 (77%) solid tumor models, but 0/7 ALL xenografts. The modest activity observed for MLN0128 against the PPTP preclinical models is similar to that previously reported for another TOR kinase inhibitor.

KW - Developmental therapeutics

KW - MTOR inhibitor

KW - Preclinical testing

UR - http://www.scopus.com/inward/record.url?scp=84901988327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901988327&partnerID=8YFLogxK

U2 - 10.1002/pbc.24989

DO - 10.1002/pbc.24989

M3 - Article

C2 - 24623675

AN - SCOPUS:84901988327

VL - 61

SP - 1486

EP - 1489

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 8

ER -